

In the specification:

Please amend the paragraph beginning at page 5, line 9 as follows:

a' R₃ and R₄ independently of each other are hydrogen, halogen, methyl, C₁₋₄-alkyl, aryl, heteroaryl wherein aryl and heteroaryl residues in turn may be substituted in one or more positions independently of each other by halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-alkylsulphonyl, methanesulphonamido, acetyl, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, amino, methylamino, dimethylamino, or acetamido;

Please amend the paragraph beginning at page 6, line 27 as follows:

a' In formula (II), R₃ and R₄ independently of each other are hydrogen, halogen, methyl, C₁₋₄-alkyl, aryl, heteroaryl wherein aryl and heteroaryl residues in turn may be substituted in one or more positions independently of each other by halogen, C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-alkylsulphonyl, methanesulphonamido, acetyl, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, amino, methylamino, dimethylamino or acetamido; or

Please amend the paragraph beginning at page 8, line 2 as follows:

a' According to the present invention, a class of novel compounds has been developed which bind to the 5-HT_{2c} receptor (agonists and/or antagonists) and which therefore may be used for the treatment of serotonin-related disorders.